Frequent biopharmaceutical company backer Deerfield Management Co. LP is investing $635m in a New York City life science campus with $540m in financing from Blackstone Real Estate and others to buy and renovate a building at 345 Park Ave. South with 300,000 square feet of office and lab space that will be made available at affordable rates to early-stage companies emerging from academic, government, industry and nonprofit groups.
Finance Watch: Deerfield Invests $635m In New York Start-Ups, Pledges $2bn Globally By 2030
Private Company Edition: Deerfield is funding a new life science campus. Also, BioFractura gets up to $67.4m in BARDA contract in recent grant and government deal surge, Mission Bay raises a $60m fund and Amphivena closes a $62m VC round.
